IL6 and COVID-19: A clinical study found that COVID-19 patients without other comorbidities but diabetes that had higher serum levels of inflammation-related biomarkers such as IL-6 were susceptible to a cytokine storm, leading to rapid deterioration of COVID-19 [27].